US 11590223
Dosing strategy that mitigates cytokine release syndrome for therapeutic antibodies
granted A61KA61K2039/505A61K2039/507
Quick answer
US patent 11590223 (Dosing strategy that mitigates cytokine release syndrome for therapeutic antibodies) held by REGENERON PHARMACEUTICALS, INC. expires Mon Feb 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Feb 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Feb 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 53
- CPC classes
- A61K, A61K2039/505, A61K2039/507, A61K2039/5156, A61K2039/5158